Sfoglia per AUTORE
BOSTER A
Collezione AOU San Luigi di Orbassano
Items : 2
Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years. in Multiple sclerosis journal - experimental, translational and clinical / Mult Scler J Exp Transl Clin. 2020 Dec 18;6(4):2055217320972137. doi: 10.1177/2055217320972137. eCol
2020
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Firmino I; Cavalier SJ; Freedman MS; Bertolotto A; Boster A; Horáková D; Jacobs AK; Thangavelu K; Daizadeh N; Poole EM; Baker DP; Margolin DH; Ziemssen T;
Best Practices for Long-Term Monitoring and Follow-Up of Alemtuzumab-Treated MS Patients in Real-World Clinical Settings. in Frontiers in neurology / Front Neurol. 2019 Mar 22;10:253. doi: 10.3389/fneur.2019.00253. eCollection 2019.
2019
AOU San Luigi di Orbassano
AOU San Luigi di Orbassano
Oreja-Guevara C; Meuth SG; Limmroth V; Lee JM; Habek M; Cruz DD; de Seze J; Celius EG; Boster A; Bertolotto A; LaGanke C; Bass AD; Traboulsee A; Carruthers R; Barclay K; Pagnotta P; Vos C; Ziemssen T; Baker DP; Wijmeersch BV;